Navigation Links
STEMCELL Technologies Introduces a New Animal Component-Free, Serum-Free Medium for Culturing Human Mesenchymal Stem Cells
Date:4/28/2009

STEMCELL Technologies, Inc. today announced the release of MesenCult®-ACF Medium, the first defined, animal component-free (ACF) and serum-free medium for culturing human mesenchymal stem cells (MSCs).

Vancouver, B.C. (PRWEB) April 28, 2009 -- STEMCELL Technologies, Inc. today announced the release of MesenCult®-ACF Medium, the first defined, animal component-free (ACF) and serum-free medium for culturing human mesenchymal stem cells (MSCs).

MesenCult®-ACF Medium supports long-term growth of MSCs with retention of multi-lineage differentiation potential. In addition, MSCs cultured in MesenCult®-ACF Medium expand faster and show a significant reduction in hematopoietic cell contamination at early passages compared to serum-containing media.

"MesenCult®-ACF Medium is a very important addition to our product portfolio and indicates our strong interest in remaining at the cutting edge of scientific and preclinical work in the stem cell arena," says Dr. Allen Eaves, President and CEO of STEMCELL Technologies.

There is considerable interest in using mesenchymal stem cells as therapeutic agents for the treatment of a wide variety of diseases. Because of this clinical interest, there is a need to culture the cells in animal component-free culture systems, in order to minimize the risk associated with disease transmission and immune rejection of transplanted cells. The availability of MesenCult®-ACF Medium will greatly facilitate advances in efforts to assess the therapeutic relevance of mesenchymal stem cells.

Furthermore, the removal of undefined components within the medium reduces the variability traditionally associated with culture of these cells and allows for more consistent research and development work on this very important cell type.

For more information about MesenCult®-ACF Medium, please visit http://www.stemcell.com/product_catalog/hu_mesencult-acf.aspx.

Contact
Kristy Favell, MSc, Assistant Product Manager - Neural and Mesenchymal Cell Biology
STEMCELL Technologies Inc
604.668.0875

About STEMCELL Technologies
STEMCELL Technologies, a privately-owned biotechnology company, is a leader in specialty cell culture media, cell separation products and ancillary reagents for life science research. Driven by science, STEMCELL delivers over 900 products to more than 70 countries worldwide. To learn more about how STEMCELL helps to make research work, visit www.stemcell.com

###

Read the full story at http://www.prweb.com/releases/stemcelltechnologies/mesencultacf/prweb2365414.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Neuralstem Responds to New StemCells, Inc. Lawsuit
2. Neuralstem Sues StemCells, Inc. Over New Patent
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. China Medical Technologies Receives SFDA Approval for Its Bladder Cancer FISH Probe
5. Dr. Susan Weinschenk, Chief of Technical Staff and Services, Speaks on Neuro Web Design at Persuasive Technologies 2009 Conference and Voices That Matter Web Design Conference
6. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
7. Waters and University of Warwick Sign Research Agreement Designed to Foster Adoption of Novel MS Technologies
8. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
9. Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results
10. Vertebral Technologies Receives Award for InterFuse(R) Interbody Fusion System
11. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
Breaking Biology Technology:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
Breaking Biology News(10 mins):